N/A N=33 Young Adult Eating Habits
Eating Behavior · Eating Habit
Primary: Change in Brain Response From Baseline to 2-weeks Post High UPF or 2 Weeks no UPF Diet — 0.02; 0.13 arbitrary units
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=353 Testing a Digital Intervention for Adolescents
Rumination · Stress, Psychological
Primary: Change in Perceived Stress [Perceived Stress Scale (PSS)] — 26.33; 25.26; 22.01; 24.67 score on a scale — p=<.001
N/A N=23 Insulin Resistance in Adolescents
Insulin Resistance
Primary: Linear Relationship Between HOMA-IR and Cognitive Function (R-squared) — 0.205; 0.299; 0.738; 0.0264 R-squared — p=0.162
N/A N=88 Adolescent Interventions to Manage Self-regulation of T1D (AIMS T1D)
Self-regulation · Medication Adherence
Primary: Change From Baseline in Youth Executive Function (Behavioral EF) at 8 Weeks (Z-score) — 0.02; -0.02 z-score
Phase 4 N=203 Study in Adolescents With Schizophrenia or Bipolar Disorder
Bipolar I Disorder · Schizophrenia
Primary: Mean Change From Baseline to 52 Weeks in Body Mass Index (BMI) for All Participants — 3.64; 2.83 kilograms per meter squared (kg/m^2) — p=0.150
Phase 1 N=497 Middle School to High School Transition Project: Depression and Substance Abuse Prevention
Depression · Substance-Related Disorders
Primary: Change in Short Moods and Feelings Questionnaire (SMFQ) — 2.19; 1.21 units on a scale — p=<0.05
Phase 3 N=50 The Adrenal Contribution to Androgen Production in Girls During Puberty
Development
Primary: 17-hydroxyprogesterone Response to ACTH — 2.4; 3.7; 3.1; 2.9 ng/mL
N/A N=123 Technology-Based Prevention for Adolescents in Primary Care
Substance Use
Primary: Enrollment and Recruitment Rate — 61; 62 Participants
N/A N=46 Activity, Adiposity, and Appetite in Adolescents 2
Obesity · Metabolic Disease · Insulin Sensitivity
Primary: Appetite- Subjective — 9239.4; 7879.6; 6130.5; 8970.0 score on a scale*min
Phase 3 N=302 Aripiprazole in Adolescents With Schizophrenia
Schizophrenia
Primary: Change in Positive and Negative Syndrome Scale (PANSS) Total Score — -26.7; -28.6; -21.2 points — p=0.05
N/A N=288 Oral Health Educational Methods in Adolescence
Adolescent Behavior
Primary: Knowledge Score — 11; 13; 11; 13 score on a scale — p=0.001
Early Phase 1 N=6 Investigation of Female Reproductive Hormone Dynamics During Adolescence
Menstruation Disturbances
Primary: Ovulation in Cycle 2 — 3; 2 Participants
N/A N=15 Adolescent Attention to Emotion Study
Depression
Primary: Affect-biased Attention Following Neurofeedback (Immediately Post-Intervention) — .41 Proportion (0-1) — p=.004
N/A N=31 Activity, Adiposity, and Appetite in Adolescents 2 Intervention
Obesity · Energy Balance · Appetite
Primary: Appetite- Subjective — 6282; 8738 score*minute
N/A N=43 PureWick™ Adolescent Study
Healthy Volunteers, Adolescent
Primary: Performance of the PureWick System in Adolescents After HCP Placement and Self-placement — 90.40; 93.09; 87.15; 90.41 Percentage of urine captured
N/A N=176 Triple Vulnerability? Circadian Tendency, Sleep Deprivation and Adolescence
Eveningness/Sleep
Primary: Total Sleep Time (TST) Average on Weeknights Via Daily Sleep Diary — 24.72; 13.02 Minutes — p=0.34
N/A N=146 Prevention of Adolescent Risky Behaviors: Neural Markers of Intervention Effects
Risk-Taking · Adolescent Behavior
Primary: Changes in Emotional Regulation — 54.43; 52.02; 54.47; 60.77 T Score — p=0.003
N/A N=66 Congenital Heart Adolescents: Program of Transition Evaluation Research
Congenital Heart Defects
Primary: Transition Readiness Assessment Questionnaire (TRAQ) Score — 2.77; 2.95; 3.80; 3.92 units on a scale
N/A N=168 A Study Examining Adolescents With Non-Suicidal Self-Injury
Self-Injurious Behavior · Deliberate Self-Harm
Primary: Self-Injurious Thoughts and Behaviors Interview (SITBI) - Lifetime Episodes — 73.29; 0 episode count
N/A N=109 Improving Diabetes in Emerging Adulthood
Diabetes Mellitus, Type 1
Primary: Hemoglobin A1c — 9.6; 9.8; 8.5; 10.9 Percentage (%) of glycated hemoglobin — p=.219
Phase 3 N=50 Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: For Part A, Pharmacokinetic (PK) Parameter: AUCtau of EVG — 31620.9 ng•h/mL
Phase 4 N=104 The Health Influences of Puberty (HIP) Study
Obesity · Insulin Resistance · Gonadal Dysfunction
Primary: Insulin Sensitivity — 8.559; 3.425; 3.756; 2.985 x10-4/min-1/mIU/mL
Phase 4 N=12 Trial of Aripiprazole in the Treatment of CD in Adolescents
Conduct Disorder
Primary: The Primary Outcome Efficacy Measure: Rating of Aggression Against People and/or Property Scale (RAAPP) (Kemph et al 1993) — 1.7 units on a scale
Phase 2 N=35 Neuroscience-Informed Treatment Development for Adolescent Alcohol Use
Alcohol Drinking · Control
Primary: Quantifying the Difference in Glutamate Levels (mmol/kg) During N-Acetylcysteine Versus Placebo in the Anterior Cingulate Brain Region. — 15.7527667; 15.6265229 mmol/kg…
N/A N=32 Activating and Connecting Teens (ACT) Study
Depression
Primary: Depression — 9.63 score on a scale
Phase 2 N=1,721 Trial of Activity for Adolescent Girls (TAAG)
Cardiovascular Diseases · Heart Diseases · Obesity
Primary: MET-weighted MVPA: Daily Minutes of Moderate-to-vigorous Physical Activity (MVPA) Weighted by Metabolic Equivalent of Task (MET) — 136.5; 136.9 Minutes of MET-weighted…
N/A N=223 Self-guided Treatment for Adolescents Navigating Depression
Depressive Symptoms · Depression · Depressive Disorder
Primary: Depressive Symptom Severity at Post-intervention — 8.39; 11.03 units on a scale — p=<0.001
N/A N=36 Improving Adherence in Adolescents and Young Adults With Bipolar Disorder
Bipolar Disorder
Primary: Change From Baseline in the Tablet Routine Questionaire (TRQ) "Past Month" Item at 24 Weeks — 21.5; 28.0 percent of medications not taken
Phase 3 N=157 Varenicline for Adolescent Smoking Cessation
Nicotine Dependence
Primary: Number of Participants With Cotinine-confirmed 7-day Point Prevalence Abstinence at the End of Treatment — 4; 4 Participants
N/A N=12 Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)
Diabetes Mellitus, Insulin-Dependent
Primary: Insulin Sensitivity — 8.6; 6.2; 5.8; 4.8 mg/kg/min